Strongest evidence
The most robust finding is for increased 25-hydroxyvitamin D levels (high evidence strength; 5 of 5 studies beneficial, moderate effect size). Doses ranged from 1000–7000 IU/day, with effects typically seen within 8–12 weeks. Moderate-strength evidence supports improved insulin sensitivity (5 of 6 studies beneficial, mixed effect sizes) and reduced HOMA-IR (3 of 4 meta-analyses beneficial, small effect), primarily in people with diabetes, prediabetes, or PCOS. Vitamin D also shows moderate evidence for reducing C-reactive protein (3 of 4 studies beneficial, moderate effect) in obese/overweight adults and those with diabetes.
Mixed or weaker evidence
Low-strength evidence covers multiple outcomes where findings are inconsistent or preliminary. For LDL cholesterol, total cholesterol, body mass index, fasting blood glucose, and triglycerides, most meta-analyses report neutral effects, with only 1–2 of 4 studies showing a small benefit — often limited to specific clinical subgroups (e.g., MAFLD or diabetes patients). Reduced inflammation (in autoimmune arthritis) and improved quality of life (in Alzheimer’s, urticaria, breast cancer) each showed 3 of 3 or 4 of 4 studies beneficial, but evidence strength is low due to small study counts and possible publication bias. Reduced interleukin-6 showed 2 of 3 studies beneficial at a very low dose (200 IU/day), but is considered preliminary.
Effective dose patterns
Only a few outcomes reported specific dose ranges. For increasing 25-hydroxyvitamin D levels, studies used 1000–7000 IU/day (or weekly dosing up to 100,000 IU). For quality of life, one study specified 4000 IU/day or 60,000 IU/week. Most other syntheses did not report consistent dose information, making dose-response conclusions difficult.
Population insights
Beneficial effects across multiple outcomes were most frequently observed in people with diabetes or prediabetes, obese/overweight individuals, and those with documented vitamin D deficiency. Clinical populations (PCOS, MAFLD, autoimmune arthritis) also showed benefits in some outcomes. Healthy, non-deficient populations were less studied or showed neutral results.
Notable caveats
- Publication bias is flagged in several syntheses — null-result studies may be less likely to be published or indexed.
- Many studies used co-supplementation (with magnesium, vitamin E, probiotics, etc.), making it hard to isolate vitamin D’s effect.
- Doses, forms (D2 vs. D3), and study durations were often unreported, limiting practical recommendations.
- Most study samples were small, and evidence bases are often limited to 3–4 studies per outcome, warranting cautious interpretation.